TZIELD
Biological
SANOFI-AVENTIS U.S. LLC
Total Payments
$7.7M
Transactions
35,296
Doctors
16,262
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.8M | 27,724 | 14,407 |
| 2023 | $1.9M | 7,520 | 4,054 |
| 2022 | $2,897 | 52 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 269 | 36.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.6M | 1,120 | 34.0% |
| Food and Beverage | $1.1M | 32,592 | 14.1% |
| Consulting Fee | $742,866 | 136 | 9.7% |
| Travel and Lodging | $420,874 | 1,174 | 5.5% |
| Space rental or facility fees (teaching hospital only) | $8,850 | 5 | 0.1% |
Payments by Type
General
$4.9M
35,027 transactions
Research
$2.8M
269 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus | SANOFI US SERVICES INC. | $2.7M | 20 |
| Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes | SANOFI-AVENTIS U.S. LLC | $31,725 | 0 |
| Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants With at Least Two Autoantibodies and Dysglycemia) | SANOFI US SERVICES INC. | $29,736 | 0 |
| Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants With at Least Two Autoantibodies and Dysglycemia) | SANOFI-AVENTIS U.S. LLC | $13,500 | 0 |
| An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes | SANOFI-AVENTIS U.S. LLC | $12,925 | 0 |
Top Doctors Receiving Payments for TZIELD
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $2.3M | 233 |
| , M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $186,332 | 122 |
| , DNP, APRN | Family | Council Bluffs, IA | $141,693 | 277 |
| , M.D | Pediatric Endocrinology | Louisville, KY | $137,104 | 101 |
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $133,335 | 55 |
| , M.D | Pediatric Endocrinology | Chicago, IL | $131,205 | 113 |
| , M.D | Endocrinology, Diabetes & Metabolism | Philadelphia, PA | $128,946 | 80 |
| , DO | Pediatrics | Saint Joseph, MO | $125,917 | 115 |
| , MD | Endocrinology, Diabetes & Metabolism | Camp Springs, MD | $124,494 | 101 |
| , M.D | Endocrinology, Diabetes & Metabolism | Memphis, TN | $123,047 | 84 |
| , M.D | Pediatric Endocrinology | Atlanta, GA | $116,898 | 114 |
| , MD | Pediatric Endocrinology | Tampa, FL | $113,783 | 67 |
| , M.D | Endocrinology, Diabetes & Metabolism | Albany, NY | $111,497 | 66 |
| , FNP-BC | Family | Buffalo, NY | $103,662 | 152 |
| , M.D | Specialist | Bartlett, TN | $95,225 | 38 |
| , MD | Pediatric Emergency Medicine | Buffalo, NY | $94,299 | 66 |
| , M.D | Pediatric Endocrinology | Jacksonville, FL | $81,306 | 15 |
| , MD | Pediatric Endocrinology | Richmond, VA | $81,238 | 52 |
| , MD | Pediatric Endocrinology | Orlando, FL | $72,461 | 59 |
| , MD | Endocrinology, Diabetes & Metabolism | Farmington Hills, MI | $69,772 | 83 |
| , MD | Pediatric Endocrinology | Gainesville, FL | $69,004 | 22 |
| , M.D | Internal Medicine | Bethpage, NY | $63,146 | 53 |
| , MD | Pediatrics | Centreville, VA | $61,881 | 65 |
| , PA-C | Medical | Albany, NY | $54,179 | 78 |
| , M.D., M.S | Pediatric Emergency Medicine | Aurora, CO | $53,984 | 19 |
Ad
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $4.9M
- SANOFI US SERVICES INC. $2.8M
- GENZYME CORPORATION $82.59
- SANOFI PASTEUR INC. $27.39
Product Information
- Type Biological
- Total Payments $7.7M
- Total Doctors 16,262
- Transactions 35,296
About TZIELD
TZIELD is a biological associated with $7.7M in payments to 16,262 healthcare providers, recorded across 35,296 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2022 to 2024. In 2024, $5.8M was paid across 27,724 transactions to 14,407 doctors.
The most common payment nature for TZIELD is "Unspecified" ($2.8M, 36.7% of total).
TZIELD is associated with 5 research studies, including "A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus" ($2.7M).